NISE
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
82
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Knee Osteoarthritis
Conditions
Knee Osteoarthritis
Trial Timeline
Mar 1, 2011 โ Aug 1, 2013
NCT ID
NCT02922712About NISE
NISE is a approved stage product being developed by Dr. Reddy's Laboratories for Knee Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02922712. Target conditions include Knee Osteoarthritis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02922712 | Approved | Completed |
Competing Products
20 competing products in Knee Osteoarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| UBX0101 | Unity Biotechnology | Phase 2 | 44 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| YH23537 + Celecoxib + YH23537 placebo | Yuhan | Phase 2 | 52 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 52 |
| ASP7962 + Naproxen + Placebo | Astellas Pharma | Phase 2 | 52 |
| Capsaicin Topical Solution | Astellas Pharma | Approved | 85 |
| CGS-200-1 + CGS-200-5 + CGS-200 Vehicle | Astellas Pharma | Phase 2 | 52 |
| MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Shionogi | Phase 3 | 77 |
| Duloxetine | Shionogi | Phase 3 | 77 |
| V120083 + Naproxen + Placebo | Shionogi | Phase 2 | 52 |
| ONO-4474 + Placebo matching ONO-4474 | Ono Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine (DLX) + Placebo (PLA) | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY545694 49 mg + LY545694 105 mg | Eli Lilly | Phase 2 | 52 |
| LY517717 + enoxaparin | Eli Lilly | Phase 2 | 52 |